This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Actinium Pharmaceuticals Sponsors Webinar On Clinical Use Of Alpha Immunotherapy

NEW YORK, Nov. 27, 2012 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. will sponsor a webinar on the "Promise of Alpha Therapy".  The discussion will be broadcast and can be accessed via the link http://www.veomed.com/grandrounds?gnr=871099 on November 30, 2012 at 3:00 PM and followed by questions and answers session from the audience.  Participants will discuss their personal experience, both clinical and pre-clinical, with alpha particle immunotherapy platform-based drug candidates.  The discussion is moderated by Dr. Rosemary Mazanet and participants include Dr. David Scheinberg, Chairman, and Experimental Therapeutics Center at Memorial Sloan Kettering Cancer Center, Dr. Joseph Jurcic, Associate Attending Physician at Sloan-Kettering's Department of Leukemia and Dr. Steven Larson, Vice Chair for Research, Department of Radiology at Sloan Kettering. 

The focus of the webinar is the use of alpha radioimmunotherapy in clinical trials and preclinical models.  Dr. Scheinberg, who originated the idea of alpha immunotherapy, will discuss theoretical underpinnings of the approach and results of his preclinical experiments.  Dr. Jurcic is currently treating acute myeloid leukemia (AML) patients in clinical trials with alpha immunotherapy drug candidates and he will present his experience and results.  As a participant in clinical trials from the nuclear medicine side, Dr. Larson will provide a first-hand account on the ease of use and requirements for alpha immunotherapy.  All participants will also offer their views on the future prospects of drugs based on this platform technology. The panel discussion to be broadcast on November 30 at 3:00 PM Eastern Time, questions for participants may be submitted via apharma@actiniumpharmaceuticals.com or by phone, the details for which are as below:

Phone number: +1 (213) 493-0614Access Code: 157-776-237

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,086.63 -26.91 -0.16%
S&P 500 1,987.01 +3.48 0.18%
NASDAQ 4,473.6970 +17.6810 0.40%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs